CLINICAL AND ELECTROPHYSIOLOGICAL EVALUATION AFTER INTRAVITREAL ZIV-AFLIBERCEPT FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION.

"None of the authors has any conflicting interests to disclose."

"Supported by Fundação de Amparo à Pesquisa do Estado de São Paulo (São Paulo, Brazil), Conselho Nacional de Desenvolvimento Científico e Tecnológico (Brasília, Brazil), and the Pan–American Association of Ophthalmology/Pan–American Ophthalmological Foundation, Paul Kayser Global Award, Arlington, TX."

"This study was a prospective, interventional, nonrandomized clinical trial that adhered to the tenets of the Declaration of Helsinki. The Ethics Committee of the Federal University of São Paulo (Institutional Review Board number 707.034) and the National Research Ethics Commission (CONEP) approved the study protocol. This study was registered at clinicaltrials.gov (NCT02556723). All patients provided informed consent for the research before screening and after explanation of the nature and possible consequences of participation. The primary outcome was assessed at 26 weeks (approximately 6 months), and a longer follow-up is planned through 52 weeks (approximately 12 months). This study reports only the 26-week data."